Tuberculosis - Pipeline Review, H2 2017

Date: November 14, 2017
Pages: 365
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T74CB41CF6CEN
Leaflet:

Download PDF Leaflet

Tuberculosis - Pipeline Review, H2 2017
Tuberculosis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H2 2017, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 8, 10, 1, 61, 41 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 5, 37 and 41 molecules, respectively.

Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Tuberculosis - Overview
Tuberculosis - Therapeutics Development
Tuberculosis - Therapeutics Assessment
Tuberculosis - Companies Involved in Therapeutics Development
Tuberculosis - Drug Profiles
Tuberculosis - Dormant Projects
Tuberculosis - Discontinued Products
Tuberculosis - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Tuberculosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Tuberculosis - Pipeline by Abera Bioscience AB, H2 2017
Tuberculosis - Pipeline by Akshaya Bio Inc, H2 2017
Tuberculosis - Pipeline by Archivel Farma SL, H2 2017
Tuberculosis - Pipeline by AstraZeneca Plc, H2 2017
Tuberculosis - Pipeline by Aucta Pharmaceuticals LLC, H2 2017
Tuberculosis - Pipeline by BioDiem Ltd, H2 2017
Tuberculosis - Pipeline by BioLingus AG, H2 2017
Tuberculosis - Pipeline by Bioversys AG, H2 2017
Tuberculosis - Pipeline by Celgene Corp, H2 2017
Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2017
Tuberculosis - Pipeline by Consegna Pharma Inc, H2 2017
Tuberculosis - Pipeline by Crestone Inc, H2 2017
Tuberculosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Tuberculosis - Pipeline by Demuris Ltd, H2 2017
Tuberculosis - Pipeline by Eisai Co Ltd, H2 2017
Tuberculosis - Pipeline by Eli Lilly and Co, H2 2017
Tuberculosis - Pipeline by Ensol Biosciences Inc, H2 2017
Tuberculosis - Pipeline by EpiVax Inc, H2 2017
Tuberculosis - Pipeline by Evotec AG, H2 2017
Tuberculosis - Pipeline by FIT Biotech Oy, H2 2017
Tuberculosis - Pipeline by GangaGen Inc, H2 2017
Tuberculosis - Pipeline by GlaxoSmithKline Plc, H2 2017
Tuberculosis - Pipeline by Globeimmune Inc, H2 2017
Tuberculosis - Pipeline by Hager Biosciences LLC, H2 2017
Tuberculosis - Pipeline by Hsiri Therapeutics LLC, H2 2017
Tuberculosis - Pipeline by Immodulon Therapeutics Ltd, H2 2017
Tuberculosis - Pipeline by Immunitor Inc, H2 2017
Tuberculosis - Pipeline by ImmunoBiology Ltd, H2 2017
Tuberculosis - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
Tuberculosis - Pipeline by Johnson & Johnson, H2 2017
Tuberculosis - Pipeline by Lakewood-Amedex Inc, H2 2017
Tuberculosis - Pipeline by LegoChem Biosciences Inc, H2 2017
Tuberculosis - Pipeline by Lipotek Pty Ltd, H2 2017
Tuberculosis - Pipeline by Matinas BioPharma Holdings Inc, H2 2017
Tuberculosis - Pipeline by Medivir AB, H2 2017
Tuberculosis - Pipeline by Merck & Co Inc, H2 2017
Tuberculosis - Pipeline by Microbion Corp, H2 2017
Tuberculosis - Pipeline by Microbiotix Inc, H2 2017
Tuberculosis - Pipeline by NEARMEDIC PLUS Ltd, H2 2017
Tuberculosis - Pipeline by Novartis AG, H2 2017
Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals LLC, H2 2017
Tuberculosis - Pipeline by Otsuka Holdings Co Ltd, H2 2017
Tuberculosis - Pipeline by Pfizer Inc, H2 2017
Tuberculosis - Pipeline by QureTech Bio AB, H2 2017
Tuberculosis - Pipeline by Qurient Co Ltd, H2 2017
Tuberculosis - Pipeline by Recce Ltd, H2 2017
Tuberculosis - Pipeline by Rodos BioTarget GmbH, H2 2017
Tuberculosis - Pipeline by Sanofi, H2 2017
Tuberculosis - Pipeline by Sanofi Pasteur SA, H2 2017
Tuberculosis - Pipeline by Sequella Inc, H2 2017
Tuberculosis - Pipeline by Shionogi & Co Ltd, H2 2017
Tuberculosis - Pipeline by Spring Bank Pharmaceuticals Inc, H2 2017
Tuberculosis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Tuberculosis - Pipeline by Target Medicals LLC, H2 2017
Tuberculosis - Pipeline by Theravectys SA, H2 2017
Tuberculosis - Pipeline by TVAX Biomedical Inc, H2 2017
Tuberculosis - Pipeline by Vaccibody AS, H2 2017
Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H2 2017
Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2017
Tuberculosis - Pipeline by Vaxine Pty Ltd, H2 2017
Tuberculosis - Pipeline by Vichem Chemie Research Ltd, H2 2017
Tuberculosis - Dormant Projects, H2 2017
Tuberculosis - Dormant Projects, H2 2017 (Contd..1), H2 2017
Tuberculosis - Dormant Projects, H2 2017 (Contd..2), H2 2017
Tuberculosis - Dormant Projects, H2 2017 (Contd..3), H2 2017
Tuberculosis - Dormant Projects, H2 2017 (Contd..4), H2 2017
Tuberculosis - Dormant Projects, H2 2017 (Contd..5), H2 2017
Tuberculosis - Dormant Projects, H2 2017 (Contd..6), H2 2017
Tuberculosis - Dormant Projects, H2 2017 (Contd..7), H2 2017
Tuberculosis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Tuberculosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Abera Bioscience AB
Akshaya Bio Inc
Archivel Farma SL
AstraZeneca Plc
Aucta Pharmaceuticals LLC
BioDiem Ltd
BioLingus AG
Bioversys AG
Celgene Corp
Chongqing Zhifei Biological Products Co Ltd
Consegna Pharma Inc
Crestone Inc
Daiichi Sankyo Co Ltd
Demuris Ltd
Eisai Co Ltd
Eli Lilly and Co
Ensol Biosciences Inc
EpiVax Inc
Evotec AG
FIT Biotech Oy
GangaGen Inc
GlaxoSmithKline Plc
Globeimmune Inc
Hager Biosciences LLC
Hsiri Therapeutics LLC
Immodulon Therapeutics Ltd
Immunitor Inc
ImmunoBiology Ltd
Inovio Pharmaceuticals Inc
Johnson & Johnson
Lakewood-Amedex Inc
LegoChem Biosciences Inc
Lipotek Pty Ltd
Matinas BioPharma Holdings Inc
Medivir AB
Merck & Co Inc
Microbion Corp
Microbiotix Inc
NEARMEDIC PLUS Ltd
Novartis AG
NovoBiotic Pharmaceuticals LLC
Otsuka Holdings Co Ltd
Pfizer Inc
QureTech Bio AB
Qurient Co Ltd
Recce Ltd
Rodos BioTarget GmbH
Sanofi
Sanofi Pasteur SA
Sequella Inc
Shionogi & Co Ltd
Spring Bank Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Target Medicals LLC
Theravectys SA
TVAX Biomedical Inc
Vaccibody AS
Vakzine Projekt Management GmbH
Vaxil Bio Therapeutics Ltd
Vaxine Pty Ltd
Vichem Chemie Research Ltd
Skip to top


Summit Corporation plc - Product Pipeline Review - 2015 US$ 1,500.00 Feb, 2015 · 46 pages

Ask Your Question

Tuberculosis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: